Enzyvant Receives 2022 Rare Impact Industry Innovation Award from the National Organization for Rare Disorders (NORD) for Novel, Tissue-Based Therapy to Treat Ultra-Rare, Life-Threatening Pediatric ConditionGlobeNewsWire • 06/27/22
Myovant Sciences (MYOV) Moves 7.7% Higher: Will This Strength Last?Zacks Investment Research • 06/20/22
Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated PainGlobeNewsWire • 06/17/22
Myovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare ConferenceGlobeNewsWire • 06/03/22
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®GlobeNewsWire • 06/02/22
Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association MeetingBusiness Wire • 05/15/22
Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association MeetingBusiness Wire • 05/13/22
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/10/22
Myovant Sciences (MYOV) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 05/10/22
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022GlobeNewsWire • 05/10/22
Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in EuropeGlobeNewsWire • 05/09/22
ALTAVANT SCIENCES PRESENTS DATA SHOWING POTENTIAL FOR COMBINATION OF RODATRISTAT ETHYL AND AMBRISENTAN IN MODEL OF PULMONARY ARTERIAL HYPERTENSIONPRNewsWire • 05/06/22
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With EndometriosisGlobeNewsWire • 05/06/22
Will Myovant Sciences (MYOV) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 05/03/22
Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate CancerBenzinga • 05/02/22
ALTAVANT SCIENCES PRESENTED DATA AT ISHLT SHOWING POTENCY AND DISTRIBUTION OF BRONCHIOLITIS OBLITERANS CANDIDATE, ALTA-2530PRNewsWire • 05/02/22
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate CancerGlobeNewsWire • 04/29/22
Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on May 10, 2022GlobeNewsWire • 04/26/22
Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing CapabilitiesGlobeNewsWire • 04/21/22
Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA® in Dry and Wet Overactive Bladder PopulationsBusiness Wire • 04/19/22
Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual MeetingBusiness Wire • 04/13/22
